Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED t
In subgroups with higher LVEF and BMI, ipragliflozin improved diastolic function more than standard treatment. These results may partly support the beneficial effect of SGLT2 inhibitors on LV diastolic performance.
Authors
- Atsushi Tanaka (ORCID: https://orcid.org/0000-0003-3352-7661)
- Yosuke Okada (ORCID: https://orcid.org/0000-0003-4998-9078)
- Nozomu Kamei (ORCID: https://orcid.org/0000-0002-7686-437X)
- Kanae Takahashi (ORCID: https://orcid.org/0000-0002-7745-2342)
- Hiroyuki Hirai (ORCID: https://orcid.org/0000-0001-5325-3827)
- Hiroki Teragawa (ORCID: https://orcid.org/0000-0002-0183-2541)
- Chikage Oshita (ORCID: https://orcid.org/0000-0003-3471-2543)
- Michio Shimabukuro (ORCID: https://orcid.org/0000-0001-7835-7665)
- Isao Taguchi (ORCID: https://orcid.org/0000-0002-0330-2851)
- Koichi Node
- Yuko Uchimura
Institutions
- Fukushima Medical University (JP)
- University of Occupational and Environmental Health Japan (JP)
- Hiroshima General Hospital (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- Dokkyo Medical University Saitama Medical Center (JP)
- Social Insurance Saitama Chuo Hospital (JP)
- Osaka Metropolitan University (JP)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1186/s12933-025-02745-1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Astellas Pharma